Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 23:24:4.
doi: 10.1186/s40824-020-0182-x. eCollection 2020.

Mechanical and physio-biological properties of peptide-coated stent for re-endothelialization

In-Ho Bae  1   2 , Myung Ho Jeong  1   2   3   4 , Dae Sung Park  1   2 , Kyung Seob Lim  5 , Jae Won Shim  1   2 , Mun Ki Kim  1 , Jun-Kyu Park  6
Affiliations

Mechanical and physio-biological properties of peptide-coated stent for re-endothelialization

In-Ho Bae et al. Biomater Res. .

Abstract

Background: The aim of this study was to characterize the mechanical and physio-biological properties of peptide-coated stent (PCS) compared to commercialized drug-eluting stents (DESs).

Methods: WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met), a stimulating peptide for homing endothelial colony-forming cell was specially synthesized and coated to bare metal stent (BMS) by dopamine-derived coordinated bond. Biological effects of PCS were investigated by endothelial cell proliferation assay and pre-clinical animal study. And mechanical properties were examined by various experiment.

Results: The peptide was well-coated to BMS and was maintained and delivered to 21 and 7 days in vitro and in vivo, respectively. Moreover, the proliferation of endothelial cell in PCS group was increased (approximately 36.4 ± 5.77%) in PCS group at 7 day of culture compare to BMS. Although, the radial force of PCS was moderated among study group. The flexibility of PCS was (0.49 ± 0.082 N) was greatest among study group. PCS did not show the outstanding performance in recoil and foreshortening test (3.1 ± 0.22% and 2.1 ± 0.06%, respectively), which was the reasonable result under the guide line of FDA (less than 7.0%). The nominal pressure (3.0 mm in a diameter) of PCS established by compliance analysis was 9 atm. The changing of PCS diameter by expansion was similar to other DESs, which is less than 10 atm of pressure for the nominal pressure.

Conclusions: These results suggest that the PCS is not inferior to commercialized DES. In addition, since the PCS was fabricated as polymer-free process, secondary coating with polymer-based immunosuppressive drugs such as -limus derivatives may possible.

Keywords: Drug-eluting stent; Mechanical properties; Peptide delivery; Peptide-coated stent; Re-endothelialization.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
Surface morphologies of PCS. SEM images of before (a) and after (b) peptide coating procedure. A representative image taken under fluorescence microscopy showed FITC-conjugated PCS (c). All magnification of images was ser as 100 ×
Fig. 2
Fig. 2
In vitro peptide disappearances on stent strut. The PCS was located at inside of silicon tube and PBS was circulated through silicon tube with 150 rpm. The PCS was taken out at every designated time point and subjected to fluorescence microscopy observation
Fig. 3
Fig. 3
Proliferation of HUVEC. Cells were cultured in 24-well cell culture dish contained the 2-dimensional PCS and BMS. Results were obtained by XTT assay. Each datum point represents the mean ± SD (n = 10). *p < 0.05
Fig. 4
Fig. 4
Mechanical properties of PCS and DESs. Radial force (a) and flexibility (b) were investigated by flat plate compression and 3-point bending test, respectively. Plastic deformation result of recoil (c) and foreshortening (d) was investigated under FDA guide line. Each datum point represents the mean ± SD (n = 10). *p < 0.05, **p < 0.005
Fig. 5
Fig. 5
In vivo peptide delivery. The PCS was implanted to rabbit iliac arteries and the peptide delivery to vessels surrounding PCS was detected by FITC observation. At every designated time, the vessel surrounding PCS was isolated and subjected to fluorescence microscopy observation
See this image and copyright information in PMC

References

    1. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354(5):483–495. doi: 10.1056/NEJMra051091. - DOI - PubMed
    1. Losordo DW, Isner JM, Diaz-Sandoval LJ. Endothelial recovery: the next target in restenosis prevention. Circulation. 2003;107(21):2635–2637. doi: 10.1161/01.CIR.0000071083.31270.C3. - DOI - PubMed
    1. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193–202. doi: 10.1016/j.jacc.2006.03.042. - DOI - PubMed
    1. Van Belle E, Tio FO, Chen D, Maillard L, Kearney M, Isner JM. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol. 1997;29(6):1371–1379. doi: 10.1016/S0735-1097(97)00049-1. - DOI - PubMed
    1. Walter DH, Cejna M, Diaz-Sandoval L, Willis S, Kirkwood L, Stratford PW, Tietz AB, Kirchmair R, Silver M, Curry C, Wecker A, Yoon YS, Heidenreich R, Hanley A, Kearney M, Tio FO, Kuenzler P, Isner JM, Losordo DW. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation. 2004;110(1):36–45. doi: 10.1161/01.CIR.0000133324.38115.0A. - DOI - PubMed